Search results for "D6"

showing 10 items of 143 documents

Inhibition of dextromethorphan metabolism by moclobemide.

1998

This pilot study was conducted to evaluate the potential of the new antidepressant moclobemide to inhibit the cytochrome enzyme P4502D6 (CYP2D6) using the cough suppressant dextromethorphan as a substrate in four extensive metabolizers (EM) of debrisoquine. The subjects received seven oral doses of 20 mg dextromethorphan at 4-h intervals over 2 days (1 and 2) and subsequently moclobemide (300 mg b.i.d.) for 9 days. On days 10 and 11, they received seven doses of 20 mg dextromethorphan in addition to moclobemide. During monotreatment and combined treatment, blood was collected on days 2 and 11, respectively, for determination of dextromethorphan and its demethylated metabolites using automat…

AdultCYP2D6animal structuresMonoamine Oxidase InhibitorsAdolescentMoclobemidePharmacologyDextromethorphanchemistry.chemical_compoundPharmacokineticsOral administrationDextrorphanMoclobemideMedicineHumansDrug InteractionsBiotransformationPharmacologybusiness.industryDextromethorphanDrug interactionAntidepressive AgentsDebrisoquinechemistryArea Under CurveBenzamidesbusinessmedicine.drugPsychopharmacology
researchProduct

Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease -- possible association with a st…

1999

Abstract Background/Aims: Antibodies to cytochrome P450 2D6, also knownas LKM1-autoantibodies, are characteristic for a subgroup of patients with autoimmune hepatitis, but can also occasionally be found in hepatitis C. We observed the occurrence of LKM1-autoantibodies 4 months after liver transplantation for Wilson's disease, in close association with a steroid-resistant rejection episode, in the absence of evidence for autoimmune hepatitis or hepatitis C. Methods: Sera from several time points prior to and following transplantation were tested for LKM-reactivity by immunofluorescence, ELISA and Western blotting. Antigen specificity was confirmed by Western blotting analysis on different cy…

AdultGraft RejectionMaleTime Factorsmedicine.medical_treatmentPrednisoloneDrug ResistanceEnzyme-Linked Immunosorbent AssayAutoimmune hepatitisLiver transplantationKidneyHepatolenticular DegenerationAntibody SpecificityAzathioprinemedicineHumansAutoantibodiesHepatitisHepatologybiologybusiness.industryStomachHepatitis Cmedicine.diseaseVirologyLiver TransplantationTransplantationWilson's diseaseCytochrome P-450 CYP2D6Immunologybiology.proteinCyclosporineAntibodyViral hepatitisbusinessImmunosuppressive AgentsJournal of hepatology
researchProduct

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical hodgkin lymphoma and correlation with early FDG-PET a…

2017

In Hodgkin Lymphoma (HL), about 20% of patients still have relapsed/refractory disease and late toxic effects rate continue to rise with time. 'Early FDG-PET' and tissue macrophage infiltration (TAM) emerged as powerful prognostic predictors. The primary endpoint was to investigate the prognostic role of both early FDG-PET and TAM; the secondary endpoint was to test if early FDG-PET positivity could correlate with high TAM score. A cohort of 200 HL patients was analysed. Induction treatment plan consisted of two to six courses of ABVD and, if indicated, involved field radiation therapy. All patients repeated CT scan and FDG-PET after two cycles and after the completion of therapy. TAM in di…

AdultMaleAdolescentHodgkin’s lymphomaMacrophagePrognosiAntigens Differentiation MyelomonocyticVinblastineDisease-Free SurvivalCohort StudiesBleomycinYoung AdultAntigens CDFluorodeoxyglucose F18RecurrencePositron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsHumansCD68AgedAged 80 and overHodgkin's lymphomahematologyMacrophagesCD68; Hodgkin's lymphoma; macrophages; PET; prognosis; hematology; oncology; cancer researchAntibodies MonoclonalMiddle AgedPrognosisHodgkin DiseaseImmunohistochemistryDacarbazineTreatment OutcomePETDoxorubicinPositron-Emission Tomographyoncologycancer researchFemaleNeoplasm Recurrence LocalFollow-Up Studies
researchProduct

Hypoxic macrophages impair autophagy in epithelial cells through Wnt1: relevance in IBD.

2014

A defective induction of epithelial autophagy may have a role in the pathogenesis of inflammatory bowel diseases. This process is regulated mainly by extracellular factors such as nutrients and growth factors and is highly induced by diverse situations of stress. We hypothesized that epithelial autophagy is regulated by the immune response that in turn is modulated by local hypoxia and inflammatory signals present in the inflamed mucosa. Our results reveal that HIF-1 alpha and Wnt1 were co-localized with CD68 in cells of the mucosa of IBD patients. We have observed increased protein levels of beta-catenin, phosphorylated mTOR, and p62 and decreased expression of LC3II in colonic epithelial …

AdultMaleAdolescentImmunologyWnt1 ProteinBiologyYoung AdultImmune systemAutophagyExtracellularHumansImmunology and AllergyIntestinal MucosaWNT1Wnt Signaling PathwayPI3K/AKT/mTOR pathwayRegulation of gene expressionCD68MacrophagesTOR Serine-Threonine KinasesAutophagyWnt signaling pathwayEpithelial CellsMiddle AgedHypoxia-Inducible Factor 1 alpha SubunitInflammatory Bowel DiseasesCell HypoxiaCell biologyGene Expression RegulationFemale
researchProduct

Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects

2007

Aripiprazole, a novel antipsychotic drug, is metabolized by CYP3A4 and CYP2D6 forming mainly its active metabolite dehydroaripiprazole. In this study, aripiprazole and dehydroaripiprazole serum levels of psychiatric patients were measured and related to dose, comedication, and clinical effects including therapeutic and side effects. Patients were treated with mean doses of 20 +/- 8 mg/day of aripiprazole (median 15 mg, range 7.5-60 mg). Serum levels correlated significantly with the dose (r = 0.419; P0.01), with a mean value of aripiprazole of 214 +/- 140 ng/ml. Mean concentrations of the active metabolite dehydroaripiprazole amounted to 40% of the parent compound. Comedication with CYP3A4 …

AdultMaleCYP2D6AripiprazoleQuinolonesPharmacologydigestive systemPiperazinesCytochrome P-450 CYP3AHumansMedicineAntipsychotic drugskin and connective tissue diseasesDehydroaripiprazoleBiological PsychiatryActive metaboliteAgedCYP3A4medicine.diagnostic_testbusiness.industryMiddle AgedPsychiatry and Mental healthCytochrome P-450 CYP2D6Therapeutic drug monitoringSchizophreniaFemaleAripiprazolebusinessAntipsychotic Agentsmedicine.drugThe World Journal of Biological Psychiatry
researchProduct

Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene

2009

Abstract Background Polymorphisms of cytochrome P450 2D6 (CYP2D6) have a significant effect on the pharmacokinetics of most tricyclic antidepressants. More than 150 alleles lead to four distinct phenotypes of drug metabolism. The phenotypes are described as ultrarapid, extensive, intermediate, and poor metabolizers. Therapeutic plasma levels of CYP2D6 substrates may be difficult to achieve. Here we describe a rapid and reliable procedure for CYP2D6*4, *3, *6, and *9 genotyping. Design and methods Serum concentrations of venlafaxine and its pharmacologically active metabolite, O-desmethylvenlafaxine, were measured in patients treated with the antidepressant venlafaxine, a substrate of CYP2D6…

AdultMaleCYP2D6GenotypeDNA Mutational AnalysisMolecular Sequence DataClinical BiochemistrySingle-nucleotide polymorphismBiologyPolymerase Chain ReactionSensitivity and Specificitydigestive systemGene DuplicationGene duplicationGenotypeHumansAlleleskin and connective tissue diseasesGeneGenotypingAllelesSequence DeletionGeneticsPolymorphism GeneticBase SequenceDepressionVenlafaxine HydrochlorideReproducibility of ResultsSequence Analysis DNAGeneral MedicineMiddle AgedCyclohexanolsMolecular biologyReal-time polymerase chain reactionCytochrome P-450 CYP2D6MutationAntidepressive Agents Second-GenerationFemaleClinical Biochemistry
researchProduct

The role of cytochrome P450 2D6 in the metabolism of moclobemide.

1996

The metabolic fate of moclobemide (Ro 11-1163), a new reversible and selective inhibitor of monoamine oxidase type A (MAO-A), has been assessed in a pilot study in 2 debrisoquine poor metabolizers (PM) and 4 extensive metabolizers (EM) after multiple oral dosings of moclobemide with and without co-medication of dextromethorphan. Absorption and disposition parameters were not different between PM and EM. Concurrent application of dextromethorphan, a selective substrate of CYP2D6, did not affect the pharmacokinetics of moclobemide. These results indicate that the cytochromal isoenzyme CYP2D6 does not play a major role in the metabolic degradation of moclobemide. Limited CYP2D6 activities beca…

AdultMaleCYP2D6Monoamine Oxidase InhibitorsMoclobemidePharmacologydigestive systemIsozymeAbsorptionchemistry.chemical_compoundPharmacokineticsCytochrome P-450 Enzyme SystemMoclobemidemedicineHumansPharmacology (medical)skin and connective tissue diseasesBiological PsychiatryPharmacologyChemistryDextromethorphanMetabolismPsychiatry and Mental healthNeurologyDebrisoquineCytochrome P-450 CYP2D6BenzamidesFemaleNeurology (clinical)Drug metabolismmedicine.drugEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic …

1998

Fourteen drug free healthy volunteers and 22 psychiatric patients under psychotropic medication were phenotyped for their individual CYP2D6 activity using dextromethorphan as a probe drug. A solution containing 20 mg dextromethorphan was administered and blood was taken 60 min later for determination of dextromethorphan and metabolites in serum. For comparison, urine was collected over 8 h after ingestion of 20 mg dextromethorphan in a separate test. The CYP2D6 phenotype was determined from the ratio of dextromethorphan to dextrorphan. For genotyping, mutant alleles of the CYP2D6 gene were identified using allele-specific polymerase chain reactions. Genotyping revealed five poor metabolizer…

AdultMaleCYP2D6animal structuresGenotypeMetaboliteUrineBiologyPharmacologyDextromethorphandigestive systemchemistry.chemical_compoundDextrorphanMoclobemideGeneticsmedicineHumansGeneral Pharmacology Toxicology and Pharmaceuticsskin and connective tissue diseasesGenotypingPsychotropic DrugsDextromethorphanMiddle AgedPhenotypeCytochrome P-450 CYP2D6chemistryFemalePharmacogeneticsmedicine.drugPharmacogenetics
researchProduct

Diffuse Type of Giant-Cell Tumor of Tendon Sheath: An Ultrastructural Study of Two Cases With Cytogenetic Support

2002

Two cases of the diffuse type of giant-cell tumor of the tendon sheath (GCTTS) are described. Both tumors arose in the vicinity of large joints of the lower extremity, showing similar clinical and radiological features. Histologically, a proliferation of polygonal mononuclear cells was seen, together with osteoclastlike giant cells, foam cells, and siderophages. The tumors were poorly delineated, displaying an infiltrative pattern into the neighboring soft tissues. Immunohistochemically, strong expression of vimentin, neuron-specific enolase, A1-antitrypsin, and CD68 was found in both mono- and multinucleated tumor cells. At the ultrastructural level, mononuclear cells revealed a diverse mo…

AdultMalePathologymedicine.medical_specialtySoft Tissue NeoplasmsVimentinBiologyGiant CellsPeripheral blood mononuclear cellTranslocation GeneticChromosome PaintingPathology and Forensic MedicineImmunoenzyme TechniquesTendonsMultinucleateStructural BiologyBiomarkers TumorTumor Cells CulturedmedicineHumansCD68Giant Cell TumorsDNA NeoplasmNeurosecretory SystemsNeoplasm ProteinsTendon sheathCytoplasmGiant cellKaryotypingUltrastructurebiology.proteinFemaleUltrastructural Pathology
researchProduct

Clinicopathologic and immunohistochemical characterization of 14 cases of angioleiomyomas in oral cavity

2018

Background Angioleiomyoma (ALM) is a benign neoplasm that originates from vascular smooth muscle. It is extremely rare in oral cavity. The objective of this study was to evaluate the clinicopathological and immunohistochemical characteristics of all oral angioleiomyomas registered in a Center of Diagnosis of Oral Diseases from 1959 to 2017. Material and Methods Slides from 14 cases of ALM stained with hematoxylin and eosin (H&E) were analyzed to confirm the diagnosis. Moreover, an immunohistochemical panel with alpha-smooth muscle actin (alpha-SMA), desmin, AE1/AE3, CD68, S-100, and CD34 antibodies was performed to evaluate semi-quantitatively the positive cells. Results ALM correspond to 0…

AdultMalePathologymedicine.medical_specialtyTime FactorsH&E stainCD3403 medical and health sciences0302 clinical medicineAngioleiomyomamedicineHumansNeoplasmGeneral DentistryRetrospective StudiesOral Medicine and PathologyCD68business.industryResearch030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseImmunohistochemistrystomatognathic diseasesAngiomyomaOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASImmunohistochemistryFemaleMouth NeoplasmsSurgeryDesminMorphologic diagnosisbusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct